Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03242642 · ClinicalTrials.gov registry record · NA
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
A NA study of Mitral Valve Regurgitation, sponsored by Medtronic Cardiovascular.
- Recruiting
- Registry status
- NA
- Development phase
- 1,056
- Enrollment target
- 20
- Study locations
NCT03242642: Recruiting NA study of Mitral Valve Regurgitation, sponsored by Medtronic Cardiovascular.
NCT03242642 is a NA study of Mitral Valve Regurgitation that is actively recruiting participants, run by Medtronic Cardiovascular. The registered enrollment target is 1,056 participants, above the 718-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03242642, a NA study of Mitral Valve Regurgitation, is actively recruiting participants, sponsored by Medtronic Cardiovascular.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,056 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Primary Outcome
Composite of all-cause mortality or heart failure hospitalization
Conditions Studied
Interventions
- DEVICE Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Study Locations (20)
California
- Scripps Memorial Hospital - La Jolla
- PIH Health Good Samaritan Hospital - Los Angeles
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Keck Hospital of the University of Southern California, USC - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- El Camino Hospital - Mountain View
- Kaiser Permanente San Francisco Medical Center - San Francisco
- Stanford Hospital and Clinics - Stanford
- Los Robles Regional Medical Center - Thousand Oaks
Florida
- JFK Medical Center - Atlantis
- Morton Plant - Clearwater
- HealthPark Medical Center - Fort Myers
- North Florida Regional Medical Center - Gainesville
- Baptist Medical Center Jacksonville - Jacksonville
- University of South Florida - Tampa
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Alabama
- University of Alabama Birmingham (UAB) Hospital - Birmingham
Arizona
- Abrazo Heart Hospital - Phoenix
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2036-09-30 |
| Phase | NA |
What NCT03242642 shows while recruiting
NCT03242642 is an interventional study that assigns participants to a tested intervention. Its 1,056 participants enrollment target places it among the larger protocols in the corpus, above the 718-participant average among 11 other Mitral Valve Regurgitation trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Mitral Valve Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) is the first listed.
NCT03242642 names 20 study sites across 6 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03242642 about?
NCT03242642 is a clinical study titled "Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.". Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
What is the current status of trial NCT03242642?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,056 participants. The study started on 2017-10-23. Estimated completion is 2036-09-30.
What conditions does trial NCT03242642 study?
This clinical trial studies the following conditions: Mitral Valve Regurgitation.
What interventions are being tested in trial NCT03242642?
The interventions under investigation include: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) (DEVICE).
Who is sponsoring clinical trial NCT03242642?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03242642 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Valve Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03242642's enrollment target sits among peer trials
1,056 3rd of 11 higher than 9 of 11 other Mitral Valve Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mitral Valve Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
RECRUITING · NA
-
AltaValve Pivotal Trial
RECRUITING · NA
-
Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System
ACTIVE NOT RECRUITING · NA
-
PARTNER 3 Trial - Mitral Valve in Valve
ACTIVE NOT RECRUITING · NA
-
MitraClip REPAIR MR Study
ACTIVE NOT RECRUITING · NA
-
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372108 · 1,056 participants
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
- NCT07018869 · 1,057 participants · Phase 3
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
- NCT03588286 · 1,058 participants · NA
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
- NCT05125302 · 1,059 participants · Phase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI